Elanco Animal Health Incorporated (ELAN)
NYSE: ELANHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ELAN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $11.17B
- Forward P/E
- 17.40
- EPS (TTM)
- -$0.41
- Dividend yield
- None
- 52-week range
- 19.40 – 27.98
- Day range
- 22.16 – 22.62
- Volume / Avg
- 4.20M / 6.21M
- Beta
- —
- Shares outstanding
- 499.45M
- Next earnings
- Nov 6, 2026
52-week range
ELAN stock today
Elanco Animal Health (ELAN) closed at $22.36 on Oct 7, down 0.53% (-$0.12), versus the S&P 500's 0.22% decline. At this level, ELAN sits in the middle of its 52-week range of $19.40 to $27.98: 20.1% below the high, set on Aug 5, 2026 and 15.3% above the low. ELAN is down 1.2% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 9.3%.
Elanco Animal Health has posted a net loss over the last twelve months (EPS of -$0.41), so its P/E ratio is not meaningful. Elanco Animal Health's next earnings report is expected on Nov 6, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Elanco Animal Health
Company profileElanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Jeffrey N. Simmons
- Headquarters
- Indianapolis, IN
- Employees
- 9,400
- IPO year
- 2018
- Website
- elanco.com
Financial highlights
Full financialsIn fiscal 2025, Elanco Animal Health generated $4.71 billion in revenue, up 6.2% from fiscal 2024, its 3rd consecutive year of revenue growth. Elanco Animal Health reported a net loss of $232.0 million, compared with net income of $338.0 million a year earlier. Gross margin was 55.0% (up from 54.9%).
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.71B | $4.44B | $4.42B | $4.41B | $4.76B |
| Growth | +6.22% | +0.50% | +0.14% | -7.41% | +45.55% |
| Net income | $-232.00M | $338.00M | $-1.23B | $-78.00M | $-483.00M |
| EPS (diluted) | $-0.47 | $0.68 | $-2.50 | $-0.16 | $-0.99 |
Analyst forecast
ForecastConsensus (16 analysts)
strong_buy
Avg. price target
$31.00+38.64%
- Strong buy 4
- Buy 10
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 6, 2026
- EPS estimate
- $0.20
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.11 vs —
Elanco Animal Health peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MDGLMadrigal Pharmaceuticals Inc. | 487.72 | -1.76% | $11.27B | vs ELAN |
| BMRNBioMarin Pharmaceutical Inc. | 55.20 | -1.81% | $10.69B | vs ELAN |
| RDYDr. Reddy's Laboratories Ltd | 12.27 | -1.76% | $10.22B | vs ELAN |
| CORTCorcept Therapeutics Incorporated | 119.60 | +0.03% | $12.93B | vs ELAN |
| BBIOBridgeBio Pharma Inc. | 66.50 | -0.69% | $13.00B | vs ELAN |
| PTGXProtagonist Therapeutics Inc. | 140.92 | +1.61% | $9.12B | vs ELAN |
| AXSMAxsome Therapeutics Inc. | 172.97 | -0.79% | $9.06B | vs ELAN |
| ARWRArrowhead Pharmaceuticals Inc. | 61.48 | -0.10% | $8.68B | vs ELAN |
Indexes, lists and sector
Elanco Animal Health stock FAQ
What is Elanco Animal Health's stock price today?
ELAN last traded at $22.36 as of Oct 7, 4:00 PM EDT, down 0.53% on the day. Prices are delayed at least 15 minutes.
When is Elanco Animal Health's next earnings date?
Elanco Animal Health is expected to report earnings on Friday, November 6, 2026. Analysts expect EPS of $0.20.
Who is Elanco Animal Health's CEO?
Mr. Jeffrey N. Simmons is the chief executive officer of Elanco Animal Health Incorporated, which has about 9,400 employees.
What is the ELAN 52-week high?
The 52-week high for ELAN is $27.98 and the 52-week low is $19.40. The stock is currently 20.1% below its high.